97 related articles for article (PubMed ID: 32183096)
1. Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules.
Rinne SS; Dahlsson Leitao C; Saleh-Nihad Z; Mitran B; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183096
[TBL] [Abstract][Full Text] [Related]
2. HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.
Martins CD; Da Pieve C; Burley TA; Smith R; Ciobota DM; Allott L; Harrington KJ; Oyen WJG; Smith G; Kramer-Marek G
Clin Cancer Res; 2018 Apr; 24(8):1853-1865. PubMed ID: 29437790
[No Abstract] [Full Text] [Related]
3. The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model.
Rylova SN; Stoykow C; Del Pozzo L; Abiraj K; Tamma ML; Kiefer Y; Fani M; Maecke HR
PLoS One; 2018; 13(4):e0195802. PubMed ID: 29668724
[TBL] [Abstract][Full Text] [Related]
4. In vivo targeting of HER2-positive tumor using 2-helix affibody molecules.
Ren G; Webster JM; Liu Z; Zhang R; Miao Z; Liu H; Gambhir SS; Syud FA; Cheng Z
Amino Acids; 2012 Jul; 43(1):405-13. PubMed ID: 21984380
[TBL] [Abstract][Full Text] [Related]
5.
Qu B; Li X; Ma Y; Wang Y; Han Y; Hou G; Gao F
Dalton Trans; 2024 May; 53(18):7946-7952. PubMed ID: 38646723
[TBL] [Abstract][Full Text] [Related]
6. First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified [
Zhang M; Kang F; Xing T; Wang J; Ma T; Li G; Quan Z; Yang W; Chen X; Wang J
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1713-1724. PubMed ID: 38216779
[TBL] [Abstract][Full Text] [Related]
7. Platelet-derived growth factor receptor β-targeted positron emission tomography imaging for the noninvasive monitoring of liver fibrosis.
Li Z; Yang H; Li X; She T; Tao Z; Zhong Y; Su T; Feng Y; Shi Q; Li L; Tian R; Wang S; Cheng J; Cai H; Lu X
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1530-1543. PubMed ID: 38189910
[TBL] [Abstract][Full Text] [Related]
8. ImmunoPET imaging of human CD8
Zhao H; Wang C; Yang Y; Sun Y; Wei W; Wang C; Wan L; Zhu C; Li L; Huang G; Liu J
J Nanobiotechnology; 2021 Feb; 19(1):42. PubMed ID: 33563286
[TBL] [Abstract][Full Text] [Related]
9. Two Novel [
Kanellopoulos P; Bezverkhniaia E; Abouzayed A; Rosenström U; Tolmachev V; Orlova A
ACS Omega; 2024 Apr; 9(16):18608-18616. PubMed ID: 38680331
[TBL] [Abstract][Full Text] [Related]
10. [
Toàn NM; Vágner A; Nagy G; Ország G; Nagy T; Csikos C; Váradi B; Sajtos GZ; Kapus I; Szoboszlai Z; Szikra D; Trencsényi G; Tircsó G; Garai I
J Med Chem; 2024 May; 67(10):8261-8270. PubMed ID: 38690886
[TBL] [Abstract][Full Text] [Related]
11. Radiolabeling Diaminosarcophagine with Cyclotron-Produced Cobalt-55 and [
Lin W; Fonseca Cabrera GO; Aluicio-Sarduy E; Barnhart TE; Mixdorf JC; Li Z; Wu Z; Engle JW
Bioconjug Chem; 2024 Mar; 35(3):412-418. PubMed ID: 38411531
[TBL] [Abstract][Full Text] [Related]
12. PET imaging of CXCR4 receptors in cancer by a new optimized ligand.
Demmer O; Gourni E; Schumacher U; Kessler H; Wester HJ
ChemMedChem; 2011 Oct; 6(10):1789-91. PubMed ID: 21780290
[No Abstract] [Full Text] [Related]
13. Biodistribution Assessment of a Novel
Pavone AM; Benfante V; Giaccone P; Stefano A; Torrisi F; Russo V; Serafini D; Richiusa S; Pometti M; Scopelliti F; Ippolito M; Giannone AG; Cabibi D; Asti M; Vettorato E; Morselli L; Merone M; Lunardon M; Andrighetto A; Tuttolomondo A; Cammarata FP; Verona M; Marzaro G; Mastrotto F; Parenti R; Russo G; Comelli A
Life (Basel); 2024 Mar; 14(3):. PubMed ID: 38541733
[TBL] [Abstract][Full Text] [Related]
14. Novel CDK19-Targeted Radiotracers: A Potential Design Strategy to Improve the Pharmacokinetics and Tumor Uptake.
Dai D; Yu J; Gou W; Yang S; Li Y; Wang Z; Yang Z; Huang T; Li P; Zhu T; Hou W; Zhao Y; Xu W; Li Y
J Med Chem; 2024 Apr; 67(8):6726-6737. PubMed ID: 38570733
[TBL] [Abstract][Full Text] [Related]
15.
Rinne SS; Abouzayed A; Gagnon K; Tolmachev V; Orlova A
Sci Rep; 2021 Feb; 11(1):3631. PubMed ID: 33574368
[TBL] [Abstract][Full Text] [Related]
16. Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model.
Xu T; Ding H; Vorobyeva A; Oroujeni M; Orlova A; Tolmachev V; Gräslund T
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396753
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer.
Abouzayed A; Tano H; Nagy Á; Rinne SS; Wadeea F; Kumar S; Westerlund K; Tolmachev V; Eriksson Karlström A; Orlova A
Pharmaceutics; 2020 Oct; 12(10):. PubMed ID: 33081166
[TBL] [Abstract][Full Text] [Related]
18. Investigation of a Pharmacological Approach for Reduction of Renal Uptake of Radiolabeled ADAPT Scaffold Protein.
Vorobyeva A; Oroujeni M; Lindbo S; Hober S; Xu T; Liu Y; Rinne SS; Garousi J
Molecules; 2020 Sep; 25(19):. PubMed ID: 32998229
[TBL] [Abstract][Full Text] [Related]
19. Protein scaffolds: antibody alternatives for cancer diagnosis and therapy.
Luo R; Liu H; Cheng Z
RSC Chem Biol; 2022 Jul; 3(7):830-847. PubMed ID: 35866165
[TBL] [Abstract][Full Text] [Related]
20. Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules.
Rinne SS; Yin W; Borras AM; Abouzayed A; Leitao CD; Vorobyeva A; Löfblom J; Ståhl S; Orlova A; Gräslund T
Biomedicines; 2022 May; 10(6):. PubMed ID: 35740315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
